Sanofi Drops Anti-STAT6 Molecule, Biotech Nurix Falls About 38% at Close

Nurix Therapeutics (NRIX) shares dropped 38% in after-hours trading on Tuesday after Sanofi (SAN) decided to halt the Phase I trial of SAR448272, an oral STAT6 degrader. Sanofi notified Nurix of the decision to discontinue the clinical trial.

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

Sanofi has decided to halt studies of an experimental inflammatory disease therapy developed in partnership with Nurix Therapeutics. Nurix Therapeutics announced the decision on Tuesday, which led to a decline in its stock price in premarket trading on Wednesday.

Nurix Therapeutics (NRIX) shares fell sharply after Sanofi discontinued a clinical trial for a licensed drug. Analysts at Wells Fargo reduced their price target. The company relies on collaboration payments from partners like Roche, Gilead, and Pfizer. NRIX stock is down 16% year-to-date. Retail traders on Stocktwits showed bullish sentiment despite the setback.

Nurix Therapeutics (NRIX) shares dropped 39.8% after Sanofi halted a Phase 1 study, ending related payments and royalties. Nurix reported $1.1B in cash as of August 31, funding operations into 2029. The stock is down 12.3% YTD and 43% from its 52-week high.

Nurix Therapeutics (NRIX) shares fell 40% after Sanofi terminated a Phase 1 clinical trial for SAR448272, a STAT6 degrader. Nurix won't receive future milestone payments or royalties for this program but retains other licensed programs. The company's cash runway remains unchanged, with $1.1B expected to last into 2H 2029. Nurix's other programs, including bexobrutideg and NX-1607, are progressing in clinical trials.